Trial Profile

Phase 2 Study of tildacerfont for the Treatment of major depressive disorder(MDD)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tildacerfont (Primary)
Indications Major depressive disorder
Focus Proof of concept; Therapeutic Use
Acronyms TAMARIND
Sponsors HMNC Brain Health

Most Recent Events

06 May 2025 According to Spruce Biosciences media release, topline results from TAMARIND are anticipated in the first half of 2026.
06 May 2025 Status changed from planning to recruiting.
10 Jun 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com